About Depomed (NASDAQ:DEPO)
Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Generic Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:DEPO
- CUSIP: 24990810
- Web: www.depomedinc.com
Capitalization:- Market Cap: $330.69 million
- Outstanding Shares: 62,988,000
Average Prices:- 50 Day Moving Avg: $5.91
- 200 Day Moving Avg: $9.12
- 52 Week Range: $4.93 - $24.50
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.37
- P/E Growth: 0.45
Sales & Book Value:- Annual Revenue: $425.34 million
- Price / Sales: 0.80
- Book Value: $3.36 per share
- Price / Book: 1.60
Profitability:- EBITDA: $112.64 million
- Net Margins: -26.02%
- Return on Equity: -45.03%
- Return on Assets: -9.34%
Debt:- Debt-to-Equity Ratio: 2.71%
- Current Ratio: 0.79%
- Quick Ratio: 0.75%
Misc:- Average Volume: 1.73 million shs.
- Beta: 1.19
- Short Ratio: 8.72
Frequently Asked Questions for Depomed (NASDAQ:DEPO)
What is Depomed's stock symbol?
Depomed trades on the NASDAQ under the ticker symbol "DEPO."
How were Depomed's earnings last quarter?
Depomed, Inc. (NASDAQ:DEPO) issued its quarterly earnings results on Monday, August, 7th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by $0.52. The business had revenue of $100 million for the quarter, compared to analysts' expectations of $100.40 million. Depomed had a negative net margin of 26.02% and a negative return on equity of 45.03%. The business's quarterly revenue was down 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.27 EPS. View Depomed's Earnings History.
When will Depomed make its next earnings announcement?
Where is Depomed's stock going? Where will Depomed's stock price be in 2017?
9 brokers have issued 1-year target prices for Depomed's shares. Their forecasts range from $5.00 to $24.00. On average, they expect Depomed's stock price to reach $12.67 in the next twelve months. View Analyst Ratings for Depomed.
What are analysts saying about Depomed stock?
Here are some recent quotes from research analysts about Depomed stock:
- 1. Cantor Fitzgerald analysts commented, "After the March 28 close, DEPO announced an agreement with Starboard that replaces CEO Jim Schoeneck as well as two incumbent board members. Guidance for 1Q17 revenue was also released, $95-100M vs. FactSet estimate." (3/29/2017)
- 2. Janney Montgomery Scott analysts commented, "Recent developments in the 2013 patent litigation brought by DEPO against Purdue have resulted in DEPO filing an amended complaint claiming Purdue willfully violated its patents. The dispute pertains to DEPO's claim that Purdue's abuse-deterrent formulation of OxyContin, which was approved by the FDA on April 5, 2010 and subsequently commercialized, relies on inventions protected by patents for DEPO's Acuform?? drug delivery technology. With a potential royalty on cumulative net sales of $10 billion at stake, we have previously estimated, and continue to believe, a damage award of $200 million or more is possible, with little to no downside risk to DEPO in the process. We note our prior estimate did not contemplate an enhanced damage award that may result in a treble (3x) damages if DEPO prevails." (2/27/2017)
Who are some of Depomed's key competitors?
Some companies that are related to Depomed include AC Immune SA (ACIU), Almost Family (AFAM), ARGENX SE-ADR (ARGX), G1 THERAPEUTICS (GTHX), AxoGen (AXGN), ImmunoGen (IMGN), AngioDynamics (ANGO), MacroGenics (MGNX), Meridian Bioscience (VIVO), WAVE Life Sciences (WVE), Calithera Biosciences (CALA), Voyager Therapeutics (VYGR), Rigel Pharmaceuticals (RIGL), Achillion Pharmaceuticals (ACHN), Mesoblast Limited (MESO), Madrigal Pharmaceuticals (MDGL), AMAG Pharmaceuticals (AMAG) and SciClone Pharmaceuticals (SCLN).
Who are Depomed's key executives?
Depomed's management team includes the folowing people:
- James P. Fogarty CPA, Chairman of the Board
- Arthur J. Higgins, President, Chief Executive Officer, Director
- August J. Moretti, Chief Financial Officer, Senior Vice President
- Matthew M. Gosling, Senior Vice President, General Counsel
- Sharon D. Larkin, Senior Vice President - Human Resources and Administration.
- Gerd G. Kochendoerfer, Senior Vice President, Technical Development & Quality
- Karen A. Dawes, Independent Director
- Louis J. Lavigne Jr., Independent Director
- William T. McKee CPA, Independent Director
- Gavin T. Molinelli, Independent Director
How do I buy Depomed stock?
Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Depomed's stock price today?
One share of Depomed stock can currently be purchased for approximately $5.39.
MarketBeat Community Rating for Depomed (NASDAQ DEPO)MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Depomed (NASDAQ:DEPO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 5 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.22) |
| Consensus Price Target: | $12.67 (135.00% upside) |
Consensus Price Target History for Depomed (NASDAQ:DEPO)
Analysts' Ratings History for Depomed (NASDAQ:DEPO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/15/2017 | Piper Jaffray Companies | Set Price Target | Hold | $9.00 | N/A |  |
| 10/13/2017 | Mizuho | Reiterated Rating | Neutral | $11.00 -> $6.00 | N/A | |
| 8/8/2017 | Morgan Stanley | Downgrade | Equal Weight -> Underweight | $12.00 -> $5.00 | High | |
| 8/8/2017 | Royal Bank Of Canada | Lower Price Target | Sector Perform -> Sector Perform | $13.00 -> $10.00 | High | |
| 8/8/2017 | Janney Montgomery Scott | Downgrade | Buy -> Neutral | $18.00 -> $8.00 | High | |
| 5/15/2017 | Cantor Fitzgerald | Set Price Target | Hold | $14.00 | Medium | |
| 3/30/2017 | JMP Securities | Reiterated Rating | Outperform | $30.00 -> $16.00 | High | |
| 2/18/2017 | Roth Capital | Set Price Target | Buy | $24.00 | N/A | |
| 11/8/2016 | Leerink Swann | Set Price Target | Buy | $22.00 | N/A | |
| 3/24/2016 | Northland Securities | Initiated Coverage | Outperform | $22.00 | N/A | |
| 2/24/2016 | WallachBeth Capital | Lower Price Target | Buy | $33.00 -> $27.00 | N/A | |
(Data available from 10/19/2015 forward)
Earnings History for Depomed (NASDAQ:DEPO)Earnings History by Quarter for Depomed (NASDAQ DEPO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | $0.12 | | | | | N/A | |
| 8/7/2017 | Q2 2017 | $0.09 | ($0.43) | $100.40 million | $100.00 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.25) | ($0.43) | $99.48 million | $95.00 million | View | Listen | |
| 2/21/2017 | Q4 2016 | $0.36 | $0.48 | $123.00 million | $123.90 million | View | Listen | |
| 11/7/2016 | Q3 | $0.35 | $0.28 | $127.22 million | $111.00 million | View | Listen | |
| 8/3/2016 | Q2 | $0.26 | $0.27 | $118.20 million | $116.70 million | View | Listen | |
| 5/5/2016 | Q1 | $0.17 | $0.12 | $106.88 million | $104.60 million | View | Listen | |
| 2/22/2016 | Q415 | $0.29 | $0.16 | $110.19 million | $111.20 million | View | Listen | |
| 11/9/2015 | Q3 | $0.19 | $0.33 | $101.64 million | $105.00 million | View | Listen | |
| 7/29/2015 | Q215 | ($0.45) | $0.27 | $88.33 million | $94.30 million | View | Listen | |
| 5/11/2015 | Q115 | $0.07 | ($0.13) | $33.80 million | $31.70 million | View | Listen | |
| 2/23/2015 | Q414 | $0.07 | $0.21 | $44.66 million | $33.90 million | View | Listen | |
| 11/5/2014 | Q314 | ($0.04) | ($0.01) | $41.50 million | $51.49 million | View | Listen | |
| 8/6/2014 | Q214 | ($0.06) | ($0.03) | $38.03 million | $67.70 million | View | Listen | |
| 5/8/2014 | Q114 | $0.11 | ($0.04) | $53.57 million | $76.50 million | View | Listen | |
| 3/12/2014 | Q413 | ($0.21) | $0.72 | $19.06 million | $40.60 million | View | Listen | |
| 11/5/2013 | Q313 | $0.07 | $0.11 | $35.55 million | $37.50 million | View | Listen | |
| 8/7/2013 | Q2 2013 | ($0.05) | $0.01 | $29.87 million | $30.00 million | View | Listen | |
| 5/8/2013 | Q1 2013 | ($0.06) | ($0.10) | $28.93 million | $26.20 million | View | Listen | |
| 2/20/2013 | Q4 2012 | ($0.11) | ($0.07) | $26.48 million | $26.60 million | View | Listen | |
| 11/5/2012 | Q312 | ($0.11) | ($0.03) | $28.06 million | $33.30 million | View | N/A | |
| 8/2/2012 | | ($0.22) | ($0.28) | | | View | N/A | |
| 5/8/2012 | | ($0.24) | ($0.16) | | | View | N/A | |
| 3/8/2012 | | ($0.31) | ($0.25) | | | View | N/A | |
| 11/1/2011 | | ($0.23) | ($0.15) | | | View | N/A | |
| 8/1/2011 | | ($0.05) | ($0.11) | | | View | N/A | |
| 5/5/2011 | | $1.05 | $1.77 | | | View | N/A | |
| 3/3/2011 | | $0.06 | $0.03 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Depomed (NASDAQ:DEPO)2017 EPS Consensus Estimate: ($0.20)
2018 EPS Consensus Estimate: $0.38
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.25) | ($0.20) | ($0.23) |
| Q2 2017 | 2 | ($0.32) | ($0.04) | ($0.18) |
| Q3 2017 | 2 | ($0.05) | $0.04 | ($0.01) |
| Q4 2017 | 2 | $0.05 | $0.38 | $0.22 |
| Q1 2018 | 1 | $0.03 | $0.03 | $0.03 |
| Q2 2018 | 1 | $0.09 | $0.09 | $0.09 |
| Q3 2018 | 1 | $0.12 | $0.12 | $0.12 |
| Q4 2018 | 1 | $0.14 | $0.14 | $0.14 |
(Data provided by Zacks Investment Research)
Dividend History for Depomed (NASDAQ:DEPO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Depomed (NASDAQ:DEPO)Insider Ownership Percentage: 2.59%
Institutional Ownership Percentage: 91.25%
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/12/2017 | Arthur J Higgins | Insider | Buy | 15,000 | $9.92 | $148,800.00 | |
| 11/14/2016 | August J Moretti | CFO | Sell | 5,000 | $20.84 | $104,200.00 | |
| 9/21/2016 | Thadd M Vargas | VP | Sell | 11,250 | $25.00 | $281,250.00 | |
| 8/10/2016 | August J. Moretti | CFO | Sell | 5,000 | $21.40 | $107,000.00 | |
| 8/10/2016 | Thadd M Vargas | VP | Sell | 26,290 | $20.92 | $549,986.80 | |
| 5/23/2016 | Thadd M Vargas | VP | Sell | 15,000 | $20.00 | $300,000.00 | |
| 5/10/2016 | Thadd M Vargas | VP | Sell | 15,000 | $17.64 | $264,600.00 | |
| 5/9/2016 | August J Moretti | CFO | Sell | 5,000 | $18.00 | $90,000.00 | |
| 3/11/2016 | Thadd M Vargas | VP | Sell | 23,000 | $16.00 | $368,000.00 | |
| 12/3/2015 | August J. Moretti | CFO | Sell | 15,000 | $18.11 | $271,650.00 | |
| 6/12/2015 | Thadd M Vargas | VP | Sell | 5,000 | $20.70 | $103,500.00 | |
| 12/2/2014 | August J Moretti | CFO | Sell | 5,339 | $15.85 | $84,623.15 | |
| 12/2/2014 | James A Schoeneck | CEO | Sell | 36,727 | $15.85 | $582,122.95 | |
| 12/2/2014 | Thadd M Vargas | VP | Sell | 8,247 | $15.85 | $130,714.95 | |
| 11/19/2014 | Matthew M Gosling | VP | Sell | 71,000 | $15.36 | $1,090,560.00 | |
| 3/14/2014 | James Schoeneck | CEO | Sell | 17,000 | $14.54 | $247,180.00 | |
| 3/14/2014 | Matthew Gosling | VP | Sell | 21,875 | $14.74 | $322,437.50 | |
| 12/2/2013 | Michael Md Sweeney | CMO | Sell | 4,270 | $8.40 | $35,868.00 | |
| 12/2/2013 | Thadd Vargas | VP | Sell | 5,296 | $8.40 | $44,486.40 | |
| 5/10/2013 | James A Schoeneck | CEO | Buy | 25,000 | $5.11 | $127,750.00 | |
| 3/6/2013 | Karen A Dawes | Director | Buy | 2,000 | $5.96 | $11,920.00 | |
| 8/14/2012 | Peter D Staple | Director | Buy | 5,000 | $5.01 | $25,050.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Depomed (NASDAQ:DEPO)
Latest Headlines for Depomed (NASDAQ:DEPO)
| Source: |
|
| Date | Headline |
|---|
 | Robbins Arroyo LLP: Depomed, Inc. (DEPO) Misled Shareholders ... - Business Wire (press release)
www.businesswire.com - October 19 at 12:15 AM |
 | Robbins Arroyo LLP: Depomed, Inc. (DEPO) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - October 19 at 12:15 AM |
 | Depomed Announces Appointment of Santosh J. Vetticaden, MD, PH.D. as Senior Vice President, Chief Medical and ... - GlobeNewswire (press release)
globenewswire.com - October 18 at 7:15 PM |
| Depomed Announces Appointment of Santosh J. Vetticaden, M.D., PH.D. as Senior Vice President, Chief Medical and Scientific Officer
finance.yahoo.com - October 18 at 7:15 PM |
| DEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses In Excess of $500,000 to Contact the Firm
finance.yahoo.com - October 17 at 6:37 PM |
| DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 - DEPO
finance.yahoo.com - October 17 at 4:38 AM |
 | EQUITY ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses Exceeding $500,000 to Contact the Firm
feeds.benzinga.com - October 16 at 9:14 PM |
| DEPO DEADLINE TOMORROW: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Depomed, Inc. and a Lead Plaintiff Deadline of October 17, 2017
finance.yahoo.com - October 16 at 6:34 PM |
| Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Depomed, Inc. (DEPO)
finance.yahoo.com - October 16 at 6:34 PM |
| DEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 16 at 6:34 PM |
| DEPO FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Depomed, Inc. (DEPO) & Lead Plaintiff Deadline: October 17, 2017
finance.yahoo.com - October 16 at 6:34 PM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 – DEPO
finance.yahoo.com - October 16 at 6:34 PM |
 | EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Depomed, Inc. - DEPO - PR Newswire (press release)
www.prnewswire.com - October 14 at 4:29 AM |
 | Depomed, Inc. (DEPO) Rating Reiterated by Mizuho
www.americanbankingnews.com - October 14 at 12:36 AM |
| DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 13 at 11:26 PM |
| Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Depomed, Inc. (DEPO)
finance.yahoo.com - October 13 at 6:22 PM |
| ETFs with exposure to Depomed, Inc. : October 13, 2017
finance.yahoo.com - October 13 at 6:22 PM |
| Valeant: A Problem…Or Just More Noise?
finance.yahoo.com - October 13 at 6:22 PM |
| EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Depomed, Inc. - DEPO
finance.yahoo.com - October 13 at 6:22 PM |
| OCTOBER 17 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and ... - GlobeNewswire (press release)
globenewswire.com - October 12 at 6:38 PM |
| OCTOBER 17 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
feeds.benzinga.com - October 12 at 3:15 PM |
 | DepoMed Inc (DEPO) PT Lowered to $6 at Mizuho Securities - StreetInsider.com
www.streetinsider.com - October 12 at 12:23 AM |
| UPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 11 at 7:21 PM |
 | BRIEF-Depomed provides information on impact of hurricane Maria to supply of NUCYNTA ER
www.businessinsider.com - October 11 at 1:38 AM |
| Depomed Provides Product Supply Information Following Hurricane Maria
finance.yahoo.com - October 11 at 1:38 AM |
| Depomed Provides Product Supply Information Following Hurricane Maria - GlobeNewswire (press release)
globenewswire.com - October 10 at 3:34 PM |
| ONE WEEK DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 10 at 3:34 PM |
| DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 9 at 6:14 PM |
| Depomed, Inc. (DEPO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 7 at 10:44 PM |
| The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Depomed, Inc. Shareholders and a Lead Plaintiff Deadline of October 17, 2017 (DEPO)
finance.yahoo.com - October 4 at 4:30 PM |
| DEADLINE APPROACHING: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 4 at 4:30 PM |
| DEPO EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Depomed, Inc. and a Lead Plaintiff Deadline of October 17, 2017
finance.yahoo.com - October 3 at 5:42 PM |
| DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 3 at 5:42 PM |
| Can Depomed Inc (DEPO) Improve Your Portfolio Returns?
finance.yahoo.com - October 3 at 7:50 AM |
| DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 3 at 7:50 AM |
 | UPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
www.nasdaq.com - September 30 at 8:47 PM |
| DEPO LOSS NOTICE: Rosen Law Firm Reminds Depomed, Inc. Investors of Important Deadline in Class Action – DEPO - GlobeNewswire (press release)
globenewswire.com - September 30 at 6:41 AM |
| DEPO LOSS NOTICE: Rosen Law Firm Reminds Depomed, Inc. Investors of Important Deadline in Class Action – DEPO
feeds.benzinga.com - September 29 at 11:22 AM |
 | Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Depomed, Inc.
www.thestreet.com - September 27 at 6:44 PM |
| Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Depomed, Inc. (DEPO) and Encourages Investors to Contact the Firm
www.businesswire.com - September 27 at 6:44 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 - DEPO
finance.yahoo.com - September 25 at 4:19 PM |
| Lawsuit for Investors in Depomed Inc. (NASDAQ: DEPO) Shares Announced by Shareholders Foundation
finance.yahoo.com - September 25 at 4:19 PM |
| APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 25 at 4:19 PM |
| Scott+Scott, Attorneys at Law, LLP Reminds Investors of October ... - PR Newswire (press release)
www.prnewswire.com - September 22 at 4:53 PM |
| ETFs with exposure to Depomed, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 4:53 PM |
| Depomed, Inc. :DEPO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
finance.yahoo.com - September 21 at 5:53 PM |
| Scott+Scott, Attorneys at Law, LLP Reminds Investors of October 17th Lead Plaintiff Deadline in Securities Class Action Against Depomed, Inc. (DEPO)
finance.yahoo.com - September 21 at 5:53 PM |
| EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 21 at 5:53 PM |
| DEPOMED INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages ... - PR Newswire (press release)
www.prnewswire.com - September 20 at 11:47 PM |
| The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Depomed, Inc. Shareholders and a Lead Plaintiff Deadline of October 17, 2017 (DEPO)
finance.yahoo.com - September 20 at 6:46 PM |
Depomed (DEPO) Chart for Thursday, October, 19, 2017
